Toll-like receptors and cytokines/cytokine receptors polymorphisms associate with non-response to hepatitis B vaccine

Vaccine

Volumn 29, Issue 4, 2011, Pages 706-711

  Chen, Jie ^a   Liang, Zhenglun ^b   Lu, Fengmin ^a   Fang, Xin ^b   Liu, Shuang ^c   Zeng, Ying ^d   Zhu, Fengcai ^e   Chen, Xiangmei ^a   Shen, Tao ^a   Li, Jie ^a   Zhuang, Hui ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d Shenzhen Kangtai Biological Products Co Ltd   (China)

^e JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Cytokine receptors; Cytokines; Hepatitis B vaccine; Non responder; Polymorphisms; Toll like receptors

Indexed keywords

CYTOKINE RECEPTOR; HEPATITIS B VACCINE; TOLL LIKE RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GENETIC ANALYSIS; HAPLOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

CYTOKINES; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CYTOKINE; TOLL-LIKE RECEPTORS;

EID: 78650532203     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.023     Document Type: Article

References (52)

1. Ganem D., Prince A.M., Hepatitis B virus infection natural history and clinical consequences. N Engl J Med 2004, 350(11):1118-1129.
2. Da Villa G., Piccinino F., Scolastico C., Fusco M., Piccininoo R., Sepe A. Long-term epidemiological survey of hepatitis B virus infection in a hyperendemic area (Afragola, southern Italy): results of a pilot vaccination project. Res Virol 1998, 149(5):263-270.
3. Chen H.L., Chang M.H., Ni Y.H., Hsu H.Y., Lee P.I., Lee C.Y., et al. Seroepidemiology of hepatitis B virus infection in children-10 years of mass vaccination in Taiwan. J Am Med Assoc 1996, 276(11):906-908.
4. Ni Y.H., Chang M.H., Huang L.M., Chen H.L., Hsu H.Y., Chiu T.Y., et al. Hepatitis B virus infection in children and adolescent in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001, 135(9):796-800.
5. Kao J.H., Hsu H.M., Shau W.Y., Chang M.H., Chen D.S. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001, 139(3):349-352.
6. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997, 336(26):1855-1859.
7. Lu F.M., Zhuang H. Management of hepatitis B in China. Chin Med J 2009, 122(1):3-4.
8. Rendi-Wagner P., Kundi M., Stemberger H., Wiedermann G., Holzmann H., Hofer M., et al. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 2001, 19(15-16):2055-2060.
9. Das K., Gupta R.K., Kumar V., Kar P. Immunogenicity and reactogenicity of a recombinant hepatitis B vaccine in subjects over age of forty years and response of a booster dose among nonresponders. World J Gastroenterol 2003, 9(5):1132-1134.
10. Clemens R., Sanger R., Kruppenbacher J., Hobel W., Stanbury W., Bock H.L., et al. Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule-results of a post-marketing surveillance. Vaccine 1997, 15(4):349-352.
11. Zhuang G.H., Yan H., Wang X.L., Hwang L.Y., Wu Q., Wang L.R., et al. Hepatitis B revaccination in healthy non-responder Chinese children: five-year follow-up of immune response and immunologic memory. Vaccine 2006, 24(12):2186-2192.
12. Jafarzadeha A., Zarei S., Shokri F. Low dose revaccination induces robust protective anti-HBs antibody response in the majority of healthy non-responder neonates. Vaccine 2008, 26(2):269-276.
13. Rendi-Wagner P., Shouval D., Genton B., Lurie Y., Rumke H., Boland G., et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 2006, 24(15):2781-2789.
14. Averhoff F., Mahoney F., Coleman P., Schatz G., Hurwitz E., Margolis H. Immunogenicity of hepatitis B vaccines, Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998, 15(1):1-8.
15. Milich D.R., Leroux-Roels G.G. Immunogenetics of the response to HBsAg vaccination. Autoimmun Rev 2003, 2(5):248-257.
16. Vidan-Jeras B., Brinovec V., Jurcal B., LeviCnik Stezinar S., Jeras M., Bohinjec M. The contribution of HLA-Class II antigens in humoral non-response and delayed response to HBsAg vaccination. Pflugers Arch: Eur J Physiol 2000, 440(5 (Suppl.)):R188-R189.
17. Lin H.H., Liao H.W., Lin S.K., Wang L.Y. HLA and response to booster hepatitis B vaccination in anti-HBs-seronegative adolescents who had received primary infantile vaccination. Vaccine 2008, 26(27-28):3414-3420.
18. Yucesoy B., Sleijffers A., Kashon M., Garssen J., de Gruijl F.R., Boland G.J., et al. IL-1β gene polymorphisms infl{ligature}uence hepatitis B vaccination. Vaccine 2002, 20(25-26):3193-3196.
19. Höhler T., Reuss E., Freitag C.M., Schneider P.M. A functional polymorphism in the IL-10 promoter influences the response after vaccination with HBsAg and hepatitis A. Hepatology 2005, 42(1):72-76.
20. Boehme K.W., Compton T. Innate sensing of viruses by Toll-like receptors. J Virol 2004, 78(15):7867-7873.
21. Takeda K., Akira S. Toll-like receptors in innate immunity. Int Immunol 2005, 17(1):1-14.
22. Bieback K., Lien E., Klagge I.M., Avota E., Schneider-Schaulies J., Duprex W.P., et al. Hemagglutinin protein of wild-type measles virus activates Toll-like receptor 2 signaling. J Virol 2002, 76(17):8729-8736.
23. Compton T., Kurt-Jones E.A., Boehme K.W., Belko J., Latz E., Golenbock D.T., et al. Human cytomegalovirus activates infl{ligature}ammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol 2003, 77(8):4588-4596.
24. Kurt-Jones E.A., Chan M., Zhou S., Wang J., Reed G., Bronson R., et al. Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci USA 2004, 101(5):1315-1320.
25. Dhiman N., Ovsyannikova I.G., Vierkant R.A., Ryan J.E., Pankratz V.S., Jacobson R.M., et al. Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine 2008, 26(14):1731-1736.
26. Huang L.J., Pan H.X., Zhang Y.J., Zhang C.F., Zeng Y., Song X.F., et al. A study on affecting factors of non-response to recombinant hepatitis B vaccine in large scale adults. Jiangsu Med J 2008, 34(6):558-560.
27. Bowie A.G. Translational mini-review series on toll-like receptors: recent advances in understanding the role of toll-like receptors in anti-viral immunity. Clin Exp Immunol 2007, 147(2):217-226.
28. Paul W.E., Seder R.A. Lymphocyte responses and cytokines. Cell 1994, 76(2):241-251.
29. Swain S.L., Weinberg A.D., English M., Huston G. IL-4 directs the development of Th2-like helper effectors. J Immunol 1990, 145(11):3796-3806.
30. Yssel H., Fasler S., de Vries J.E., de Waal Malefyt R. Interleukin 12 (IL-12) transiently induces IFN-r transcription and protein synthesis in human CD4+ allergen-specific helper type 2 (Th2) T cell clones. Int Immunol 1994, 6(7):1091-1096.
31. Manetti R., Gerosa F., Giudizi M.G., Biagiotti R., Parronchi P., Piccinni M.P., et al. Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J Immunol 1994, 179(4):1273-1283.
32. Shi Y.Y., He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005, 15(2):97-98.
33. Lu F.M., Li T., Liu S., Zhuang H. Epidemiology and prevention of hepatitis B virus infection in China. J Viral Hepatitis 2010, 17(Suppl. 1):4-9.
34. Wang C., Tang J., Song W., Lobashevsky E., Wilson C.M., Kaslow R.A. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 2004, 39(4):978-988.
35. Kruger A., Adams P., Hammer J., Bocher W.O., Schneider P.M., Rittner C., et al. Hepatitis B surface antigen presentation and HLA-DRB1*- lessons from twins and peptide binding studies. Clin Exp Immunol 2005, 140:325-332.
36. Isogawa M., Robek M.D., Furuichi Y., Chisari F.V. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005, 79(11):7269-7272.
37. Riordan S.M., Skinner N., Kurtovic J., Locarnini S., Visvanathan K. Reduced expression of toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B. Clin Vaccine Immunol 2006, 13(8):972-974.
38. Schnare M., Barton G., Holt A.C., Takeda K., Akira S., Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001, 2(10):947-950.
39. Gavin A.L., Hoebe K., Duong B., Ota T., Martin C., Beutler B., et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006, 314(5807):1936-1938.
40. Hennig B.J., Fielding K., Broxholme J., Diatta M., Mendy M., Moore C., et al. Host genetic factors and vaccine-induced immunity to hepatitis B virus infection. PLoS One 2008, 3(3):e1898.
41. Law A.J., Kleinman J.E., Weinberger D.R., Weickert C.S. Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Hum Mol Genet 2007, 16(2):129-141.
42. Deng G., Zhou G., Zhang R., Zhai Y., Zhao W., Yan Z., et al. Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers. Gastroenterology 2008, 134:716-726.
43. Silverman T.A., Noguchi M., Safer B. Role of sequences within the first intron in the regulation of expression of eukaryotic initiation factor 2 alpha. J Biol Chem 1992, 267(14):9738-9742.
44. Capon F., Allen M.H., Ameen M., Burden A.D., Tillman D., Barker J.N., et al. A synonymous SNP of the corneodesmosin gene leads to increased mRNA stability and demonstrates association with psoriasis across diverse ethnic groups. Hum Mol Genet 2004, 13(20):2361-2368.
45. Shehata I.H., Mostafa M.M., Ziada K.W., Saeed A.M. Role of IL-13 in the pathogenesis of bronchial asthma. Egypt J Immunol 2007, 14(2):19-27.
46. Hardy C.L., Lemasurier J.S., Olsson F., Dang T., Yao J., Yang M., et al. Interleukin-13 regulates secretion of the tumor growth factor-{beta} superfamily cytokine activin A in allergic airway inflammation. Am J Respir Cell Mol Biol 2010, 42(6):667-675.
47. Seder R.A., Paul W.E. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 1994, 12:635-673.
48. Keegan A.D., Nelms K., White M., Wang L.M., Pierce J.H., Paul W.E. An IL-4 receptor region containing an insulin receptor motif is important for IL-4-mediated IRS-1 phosphorylation and cell growth. Cell 1994, 76(5):811-820.
49. Goncalves L., Albarrab B., Salmen S., Borges L., Fields H., Montes H., et al. The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation. Virology 2004, 326(1):20-28.
50. Chedid M.G., Deulofeut H., Yunis D.E., Lara-Marquez M.L., Salazar M., Deulofeut R., et al. Defect in Th1-like cells of nonresponders to hepatitis B vaccine. Hum Immunol 1997, 58(1):42-51.
51. Kardar G.A., Jeddi-Tehrani M., Shokri F. Diminished Th1 and Th2 cytokine production in healthy adult nonresponders to recombinant hepatitis B vaccine. Scand J Immunol 2002, 55(3):311-314.
52. Hsu H.Y., Chang M.H., Hsieh R.P., Ni Y.H., Chi W.K. Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum-hepatitis B surface antigen. Hepatology 1996, 24(6):1355-1360.